Quanta Services, Inc. ( PWR Quick Quote PWR - Free Report) is scheduled to report first-quarter 2021 results on May 6, before the opening bell. In the last reported quarter, the company’s top and bottom lines surpassed the Zacks Consensus Estimate by 0.2% and 24.5%, respectively. Its earnings increased 31.2% from the prior year but revenues declined 6.4%. Encouragingly, earnings topped analysts’ expectation in five of the trailing six quarters. Trend in Estimate Revision
The Zacks Consensus Estimate for earnings for the quarter to be reported has increased 1.4% over the past 60 days to 74 cents per share. The said figure indicates a 57.5% increase from the year-ago earnings of 47 cents per share. The consensus mark for revenues is $2.76 billion, suggesting 0.2% year-over-year fall.
Factors to Note
Quanta Services’ first-quarter revenues are expected to have declined owing to lower contribution from the Underground Utility and Infrastructure Solutions business. Earlier known as Pipeline and Industrial Infrastructure Services, the segment has been witnessing COVID-related downgraded commodity prices, which might have impacted the company’s overall performance. Also, the business is grappling with lack of demand stemming from decreased global travel activity associated with the pandemic and reduced contributions from larger pipeline projects.
In fact, it is expected to have grabbed lesser pipeline and industrial capital projects due to a low commodity price environment as well as reduction in customer capital budget. In addition to these issues, increased restrictions on oil and gas production activities may put a pressure on top-line results. The company expects revenues from the Underground Utility and Infrastructure business to decline more than 20% from first-quarter 2020. The consensus estimate for the segment’s revenues is pegged at $771 million, implying fall of 22.7% from $997 million reported in the year-ago period. Within the Electric Power Infrastructure Services segment, first-quarter revenues are likely to be the lowest in a year, primarily due to seasonal weather dynamics and their impact on certain construction activities. For the Electric Power unit, first-quarter operating margins are also expected to be the lowest for the year, possibly below 10%. Nonetheless, higher profitability from the LUMA joint venture and other integral unconsolidated affiliates are likely to have supported bottom-line growth in the to-be-reported quarter. Also, communications and electric operations might have added to the positives. The Zacks Consensus Estimate for the segment’s revenues is pegged at $1,967 million, implying 11.3% growth from a year ago. What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for Quanta Services this time around. The combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. The company has an Earnings ESP of 0.00% and carries a Zacks Rank #2. You can see . the complete list of today’s Zacks #1 Rank stocks here Stocks Worth a Look
Here are some companies in the Zacks
Engineering - R and D Services sector, which according to our model have the right combination of elements to post an earnings beat in their respective quarters to be reported. AECOM ( ACM Quick Quote ACM - Free Report) has an Earnings ESP of +2.93% and carries a Zacks Rank #2. Fluor Corporation ( FLR Quick Quote FLR - Free Report) has an Earnings ESP of +107.69% and carries a Zacks Rank #3. ChampionX Corporation ( CHX Quick Quote CHX - Free Report) has an Earnings ESP of +20.97% and carries a Zacks Rank #3. Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>